We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...

In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

Claro Advisors LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 15.7% in the 4th ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

(RTTNews) - Regeneron Pharmaceuticals ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...